Board of Directors Archives

Dr Leanna Read has executive, board and investment experience across a range of technology-based enterprises, particularly biotechnology. She was CEO and Chair of the CRC for Cell Therapy Manufacturing (CTM CRC) that established TekCyte, and has been Chair of TekCyte since its formation in 2018. She also chairs the second spin-out from CTM CRC, Carina Biotech Pty Ltd. Dr Read was Chief Scientist for South Australia for a four-year term until 2019.

She is a current member of several private and public sector boards including Uniseed venture capital investment company, Biosensis Pty Ltd, RSPCA SA and the Federal Government Biomedical Translation Fund Committee. Dr Read has been elected to the Australian Academy of Technology and Engineering and is a Fellow of the Australian Institute of Company Directors.

Dr Stephen Livesey is a medical doctor, a PhD, biotechnology entrepreneur and Acting Chief Executive Officer of TekCyte. He is also a long-standing member of the company’s Board of Directors. Dr Livesey has a distinguished career spanning medicine, medical research, biotechnology commercialisation and executive leadership, underpinned by a sustained commitment to translating research and innovation into real-world clinical outcomes. He co-founded LifeCell Corporation in the United States, where he was Chief Scientific Officer and Executive Vice President. LifeCell was established through a university technology transfer stemming from Dr Livesey’s invention of a cell and tissue preservation technology. This technology was commercialised through LifeCell, as the product AlloDerm, into multiple types of reconstructive surgeries. LifeCell was ultimately acquired for $US 2.9 billion. He has also served as Chief Scientific Officer and Chief Executive Officer of the Australian Stem Cell Centre, and has held executive, board and research roles across biotechnology, cell therapy and medical research organisations.

Dr Alexander Gosling has been working in the field of process and product development for 40 years, and is founding director of Invetech, a global innovation and product realisation partner. Dr Gosling sits on a number of listed and unlisted medtech company Boards and was appointed a Member of the Order of Australia for services to business through innovative support for research and development, and to the community. He was awarded an Honorary Doctorate of Engineering, and was elected a Fellow of the Academy of Technology & Engineering and a Fellow of the Institute of Engineers Australia.

Professor Rob Short is an internationally recognised materials scientist with expertise in chemistry, biomaterials and advanced materials research, development and commercialisation. He is an inventor on 10 distinct patents underpinning globally sold products including myskinTM, a burns treatment technology adopted by the UK’s National Health Service and used for more than a decade in major burns units across the UK up until 2017. Professor Short has held senior leadership roles at leading universities in the UK and Australia, helped establish advanced materials research and development companies, secured more than $250 million in grants and investment, and published more than 250 peer-reviewed papers. He is a Fellow of the Australian Academy of Technological Sciences and Engineering, the Royal Society of Chemistry, and the Institute of Materials, Minerals and Mining. He is currently Professor of Chemistry and Head of the Sustainable Materials Research Cluster at the University of Sheffield.

Charlie is a Chartered Accountant with over 45 years’ experience in science, finance and compliance. Mr Latham has had over 20 years’ experience as Company Secretary and Chief Financial Officer (CFO) of small ASX-listed entities and extensive experience as director, CFO and secretary of other companies. He has served on several audit and risk, due diligence and capital raising committees. Charlie is chair of Carina Biotech’s Audit and Risk Committee and has a Bachelor of Science (Hons) in zoology.

Share This